Skip to main content

Advertisement

SpringerLink
Log in

The tumor characteristics, treatment strategy, and prognosis in colorectal cancer patients with synchronous liver metastasis in China and the USA

  • RESEARCH
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

This study performed an analysis of clinicopathological characteristics, surgical treatment strategy, and survival for CRC patients with LM between China and the USA.

Methods

The CRC patients with simultaneous LM were identified from the Surveillance, Epidemiology, and End Results (SEER) registry and the Chinese National Cancer Center (CNCC) database from 2010 to 2017. We assessed 3-year cancer-specific survival (CSS) according to surgical treatment strategy and time period.

Results

Differences in patient age, gender, primary tumor location, tumor grade, tumor histology, and tumor stage were observed between the USA and China. Compared to the USA, a larger proportion of patients in China underwent both primary site resection (PSR) and hepatic resection (HR) (35.1% vs 15.6%, P < 0.001), and fewer patients underwent only PSR in China (29.1% vs 45.1%, P < 0.001). From 2010 to 2017, the proportion of patient who underwent both PSR and HR has increased from 13.9% to 17.4% in the USA and from 25.4% to 39.4% in China. The 3-year CSS were increasing over time in both the USA and China. The 3-year CSS of patients receiving HR and PSR were significantly higher than those receiving only PSR and patients treated with no surgery in the USA and China. There were no significant differences of 3-year CSS between the USA and China after adjustment (P = 0.237).

Conclusions

Despite the distinctions of tumor characteristics and surgical strategy in patients with LM between the USA and China, increased adoption of HR has contributed to the profound improvements of survival during recent decade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132

    Article  PubMed  Google Scholar 

  3. Lykoudis PM, O’Reilly D, Nastos K, Fusai G (2014) Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg 101(6):605–612

    Article  CAS  PubMed  Google Scholar 

  4. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259

    Article  PubMed  PubMed Central  Google Scholar 

  5. Al Bandar MH, Kim NK (2017) Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). Oncol Rep 37(5):2553–2564

    Article  CAS  PubMed  Google Scholar 

  6. Uthman YA, Ibrahim KG, Abubakar B, Bello MB, Malami I, Imam MU et al (2021) MALAT1: a promising therapeutic target for the treatment of metastatic colorectal cancer. Biochem Pharmacol 190:114657

    Article  CAS  PubMed  Google Scholar 

  7. Zeng X, Ward SE, Zhou J, Cheng ASL (2021) Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives. Cancers (Basel) 13(10)

  8. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019

    Article  CAS  PubMed  Google Scholar 

  9. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1271–1280

    Article  PubMed  Google Scholar 

  10. Gupta D, Lee JJ, Lin AY (2021) A randomized clinical trial on anterior approach vs conventional hepatectomy for resection of colorectal liver metastasis-to terminate or not to terminate the study. JAMA Surg

  11. Qiu H, Cao S, Xu R (2021) Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (London)

  12. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677–3683

    Article  PubMed  PubMed Central  Google Scholar 

  13. Guan X, Ma CX, Quan JC, Li S, Zhao ZX, Chen HP et al (2019) A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study. BMC Cancer 19(1):704

    Article  PubMed  PubMed Central  Google Scholar 

  14. Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML et al (2018) Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol 29(9):1955–1963

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27(8):1539–1546

    Article  CAS  PubMed  Google Scholar 

  16. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY et al (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31(16):1931–1938

    Article  CAS  PubMed  Google Scholar 

  17. Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M (2021) Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. JAMA Netw Open 4(8):e2118416

    Article  PubMed  PubMed Central  Google Scholar 

  18. Dai Y, Zhao W, Yue L, Dai X, Rong D, Wu F et al (2021) Perspectives on immunotherapy of metastatic colorectal cancer. Front Oncol 11:659964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xu J, Shao T, Song M, Xie Y, Zhou J, Yin J et al (2020) MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol Cancer 19(1):51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mehdorn AS, Beckmann JH, Braun F, Becker T, Egberts JH (2021) Usability of indocyanine green in robot-assisted hepatic surgery. J Clin Med 10(3)

  21. Petrowsky H, Linecker M, Raptis DA, Kuemmerli C, Fritsch R, Kirimker OE et al (2020) First long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases. Ann Surg 272(5):793–800

    Article  PubMed  Google Scholar 

  22. Guerra F, Guadagni S, Pesi B, Furbetta N, Di Franco G, Palmeri M et al (2019) Outcomes of robotic liver resections for colorectal liver metastases. A multi-institutional analysis of minimally invasive ultrasound-guided robotic surgery. Surg Oncol 28:14–8

  23. Abdalla EK, Bauer TW, Chun YS, D’Angelica M, Kooby DA, Jarnagin WR (2013) Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford) 15(2):119–130

    Article  PubMed  Google Scholar 

  24. Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG et al (2016) Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol 22(2):519–533

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chua TC, Saxena A, Liauw W, Chu F, Morris DL (2012) Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases–a systematic review. Eur J Cancer 48(12):1757–1765

    Article  PubMed  Google Scholar 

  27. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8):1311–1319

    Article  CAS  PubMed  Google Scholar 

  28. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766

    Article  PubMed  PubMed Central  Google Scholar 

  29. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239(6):818–827

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kanemitsu Y, Shitara K, Mizusawa J, Hamaguchi T, Shida D, Komori K et al (2021) Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 39(10):1098–1107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325(7):669–685

    Article  CAS  PubMed  Google Scholar 

  32. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346–1355

    Article  CAS  PubMed  Google Scholar 

  33. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T et al (2021) Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 39(4):273–284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383(23):2207–2218

    Article  PubMed  Google Scholar 

  35. Tang W, Ren L, Liu T, Ye Q, Wei Y, He G et al (2020) Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: The BECOME Randomized Controlled Trial. J Clin Oncol 38(27):3175–3184

    Article  CAS  PubMed  Google Scholar 

  36. Chaudhry S, Fields RC, Grierson PM, Lim KH (2021) Combined systemic and hepatic artery infusion pump chemo-therapy as a liver-directed therapy for colorectal liver metastasis-review of literature and case discussion. Cancers (Basel) 13(6)

  37. Peng D, Cheng YX, Cheng Y (2021) Improved overall survival of colorectal cancer under multidisciplinary team: a meta-analysis. Biomed Res Int 2021:5541613

    Article  PubMed  PubMed Central  Google Scholar 

  38. Chen CH, Hsieh MC, Lao WT, Lin EK, Lu YJ, Wu SY (2018) Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. Am J Cancer Res 8(9):1887–1898

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Zerillo JA, Schouwenburg MG, van Bommel ACM, Stowell C, Lippa J, Bauer D et al (2017) An International collaborative standardizing a comprehensive patient-centered outcomes measurement set for colorectal cancer. JAMA Oncol 3(5):686–694

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Surveillance, Epidemiology, and End Results (SEER) project for their work in data collection and availability.

Funding

This work was supported by the Sanming Project of Medicine in Shenzhen (Grant Number: SZSM201911012) and the National Key R&D Program for Young Scientists (Grant Number: 2022YFC2505700).

Author information

Author notes

  1. Shuai Jiao, Xu Guan and Haitao Niu contributed equally to this work and should be considered as co-first authors.

    Xu Guan, Yinggang Chen and Xishan Wang contributed equally to this work as co-corresponding author.

Authors and Affiliations

  1. Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    Shuai Jiao & Weiyuan Zhang

  2. Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China

    Xu Guan, Haitao Niu, Kaifeng Wang, Enrui Liu, Ran Wei & Xishan Wang

  3. Department of Colorectal Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

    Xiaolong Ma

  4. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China

    Peng Sun & Yinggang Chen

Authors
  1. Shuai Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xu Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haitao Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaolong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaifeng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enrui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weiyuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ran Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yinggang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xishan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: Xishan Wang, Yinggang Chen, and Xu Guan. Statistical analysis: Shuai Jiao, Haitao Niu, and Xiaolong Ma. Data collection or management: Xu Guan, Enrui Liu, Weiyuan Zhang and Kaifeng Wang. Manuscript writing/editing: Shuai Jiao, Xu Guan, Haitao Niu, Ran Wei, and Peng Sun. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Xu Guan, Yinggang Chen or Xishan Wang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 19 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiao, S., Guan, X., Niu, H. et al. The tumor characteristics, treatment strategy, and prognosis in colorectal cancer patients with synchronous liver metastasis in China and the USA. Int J Colorectal Dis 38, 140 (2023). https://doi.org/10.1007/s00384-023-04398-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00384-023-04398-6

Keywords

Search

Navigation